Press Releases

(Singapore, September 3, 2025) – The ISPE Singapore Affiliate Conference and Exhibition, a premier event in biopharmaceutical manufacturing, was successfully held from August 27 to 29, 2025. The conference covered critical aspects from scientific facility design to quality control, gathering cutting-edge expertise and solutions across the entire industry chain. Dr. Jun Hu, Vice President of WuXi XDC, Head of Client Enabling Center of Excellence and Head of Singapore Site Management, was invited to deliver a keynote speech and panel discussions focusing on industry innovation.

As a key component of WuXi XDC’s global strategy, the Singapore site integrates end-to-end services for antibody intermediates, drug substance and drug products. During the conference, the organizer arranged an exclusive site tour of Singapore site of WuXi XDC, inviting global biopharmaceutical participants to gain firsthand insight into advanced bioconjugate manufacturing and foster deeper international collaboration to build a new ecosystem for the industry.

• One-Stop CRDMO Model Empowers Global Customers

On August 28, Dr. Hu delivered a keynote speech on “Collaboration and Empowering Partners on ADC Development and Manufacturing” and participated in panel discussions with industry experts on key challenges and innovative practices in the CDMO field, exploring future directions for the biopharmaceutical industry.

WuXi XDC has long been dedicated to the bioconjugate field, providing end-to-end services that support the entire bioconjugates development lifecycle and accelerate the translation of medical innovations into reality. With mature technology platforms and a highly effective project management system, WuXi XDC demonstrates industry-leading efficiency in project execution, shortening the average timeline from early-stage molecule to IND stage within 15 months—significantly faster than the industry average. The completion from late-stage development to BLA filing takes only 24–36 months, providing customers with a critical time advantage in entering commercial manufacturing.

Dr. Hu highlighted that WuXi XDC’s high-quality services have been demonstrated in numerous benchmark cases. For instance, in the case of a certain biopharmaceutical company, WuXi XDC provided end-to-end support from the IND stage to critical BLA preparation, and utilized its proprietary WuXiDARx™ platform to optimize molecular structures and enhance efficacy and PK profile. This professional technical support and efficient service response earned strong recognition, leading the customer to entrust WuXi XDC with multiple ADC programs—a testament to the deep mutual trust between the two parties.

Regarding the WuXi XDC’s global strategy, Dr. Hu stated, “Since our establishment, we have adopted a global expansion strategy, with Singapore serving as a key cornerstone of commercial manufacturing overseas. Singapore plays a pivotal role in the global supply network, offering efficient logistics, well-developed infrastructure, and an open trade environment that provides solid support for global distribution of bioconjugate drugs. The Singapore site expands WuXi XDC’s global service with end-to-end capabilities for antibody intermediates, drug substance and drug products, ensuring seamless integration of R&D and manufacturing while minimizing efficiency loss from multi-party coordination. WuXi XDC will further strengthen its one-stop CRDMO business model and its ‘Enable, Follow and Win the Molecule’ strategy, advancing the development of global bioconjugates industry.”

• Multiple Pharma Companies Tour WuXi XDC’s Singapore site

 
During the conference, the site tour of WuXi XDC’s Singapore facility attracted participation from over twenty multinational pharmaceutical companies and local Southeast Asian biotech firms. The site tour included visits to the antibody intermediates & bioconjugate drug substance facilities, drug product facilities, quality control and mechanical areas, enabling participants to observe advanced technologies for bioconjugates manufacturing and deepening their recognition of WuXi XDC’s R&D and manufacturing capabilities and enhancing cross-regional biopharmaceutical collaboration.

 
Located in the Tuas Biomedical Park, the Singapore site spans approximately 25,000 square meters and is expected to achieve GMP release in the first half of 2026. Leveraging Singapore’s biomanufacturing cluster and policy advantages, the site will provide end-to-end commercial manufacturing services to serve the clients worldwide. In the future, the Singapore site will complement WuXi XDC’s existing capacity in Wuxi, China, meeting customers’ diverse production needs for bioconjugates and reinforcing the company’s leading position as a global CRDMO leader. More than a showcase of technology and capability, this site tour served as a deep engagement within the industry ecosystem. WuXi XDC is poised to reshape the global landscape of bioconjugates development and manufacturing in the industry.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com
 

Contacts
Investor: wuxixdc.ir@wuxibiologics.com

Media: wuxixdc_pr@wuxibiologics.com

BD: wuxixdc_info@wuxibiologics.com